Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Takahito Sugisaki"'
Autor:
Takashi Yokokawa, Kenichi Suzuki, Daiki Tsuji, Mari Hosonaga, Kazuo Kobayashi, Kazuyoshi Kawakami, Hitoshi Kawazoe, Tomonori Nakamura, Wataru Suzuki, Takahito Sugisaki, Takeshi Aoyama, Koki Hashimoto, Masahiro Hatori, Takuya Tomomatsu, Ayaka Inoue, Keiichi Azuma, Maimi Asano, Toshimi Takano, Shinji Ohno, Masakazu Yamaguchi
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 18745-18754 (2023)
Abstract Background Female sex and younger age are reported risk factors for chemotherapy‐induced nausea and vomiting (CINV) in highly emetogenic chemotherapy, but the underlying mechanism has not been elucidated. The purpose of this study was to c
Externí odkaz:
https://doaj.org/article/8cf3b7f0b5934cada3416f1a0aaf9b60
Autor:
Yoshinori Ito, Kazuo Kobayashi, Kazuyoshi Kawakami, Toshihiro Hama, Shunji Takahashi, Takeshi Aoyama, Kokoro Kobayashi, Shinji Ohno, Takashi Yokokawa, Daigo Shouji, Kenichi Suzuki, Tomomi Takiguchi, Hiroshi Watanabe, Takahito Sugisaki
Publikováno v:
Anticancer Research. 40:915-921
BACKGROUND/AIM This study aimed was to clarify the impact of pegfilgrastim (PEG) 3.6 mg primary prophylaxis of febrile neutropenia (FN) on the average relative dose intensity (ARDI) of neoadjuvant/adjuvant FEC-100 for breast cancer. MATERIALS AND MET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06dfca2daca06d960ee825648e3adebf
https://doi.org/10.21873/anticanres.14024
https://doi.org/10.21873/anticanres.14024
Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer
Autor:
Kazuo Kobayashi, Toshihiro Hama, Ayaka Inoue, Mitsukuni Suenaga, Kenichi Suzuki, Kazuyoshi Kawakami, Takahito Sugisaki, Takashi Yokokawa, Kensei Yamaguchi, Toshiharu Yamaguchi, Yoshiaki Machida
Publikováno v:
Oncology Research
Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::087a95cb4a74c2555560c2a8ea7aea30
http://europepmc.org/articles/PMC7841266
http://europepmc.org/articles/PMC7841266
Autor:
Yoshiaki Machida, Toshihiro Hama, Tomomi Takiguchi, Takeshi Aoyama, Takahito Sugisaki, Kazuyoshi Kawakami, Mitsukuni Suenaga, Ayaka Inoue, Kensei Yamaguchi, Takashi Yokokawa, Kenichi Suzuki, Toshiharu Yamaguchi, Kazuo Sugita
Publikováno v:
Oncology. 91:224-230
Background: A novel oral agent that consists of trifluridine and tipiracil hydrochloride (TFTD) has been established as salvage-line treatment for metastatic colorectal cancer (mCRC). Adherence to TFTD is crucial to maintaining appropriate curative e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc41ef81c0bbb9b0e5f6d712112fa605
https://doi.org/10.1159/000448717
https://doi.org/10.1159/000448717
Autor:
Takeshi Aoyama, Yoshikazu Sugimoto, Toshihiro Hama, Takahito Sugisaki, Yuma Nonomiya, Kazuyoshi Kawakami, Takashi Yokokawa, Kensei Yamaguchi, Kazuo Kobayashi, Tomomi Takiguchi, Mitsukuni Suenaga, Takeru Wakatsuki, Kenichi Suzuki
Publikováno v:
Oncology Research
Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand‐foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d144b6b7bd743af79f41d9dc3a3deed3
https://pubmed.ncbi.nlm.nih.gov/29914591
https://pubmed.ncbi.nlm.nih.gov/29914591
Autor:
Tsuyoshi Konishi, Takahito Sugisaki, Kazuyoshi Kawakami, Mitsukuni Suenaga, Satoshi Nagayama, Masashi Ueno, Takashi Yokokawa, Yosuke Fukunaga, Yoshiya Fujimoto, Toshiharu Yamaguchi, Satoshi Matsusaka, Eiji Shinozaki, Takashi Akiyoshi
Publikováno v:
Anticancer Research. 38
Background/aim Past studies have suggested that adjuvant capecitabine and oxaliplatin (CAPOX) provides decreased tumor relapse and longer survival in patients with curatively resected colon cancer. We report the first evidence of the feasibility of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3eeb08a26cba5ce74ab8c0338c0a934
https://doi.org/10.21873/anticanres.12410
https://doi.org/10.21873/anticanres.12410
Autor:
Takeshi Aoyama, Toshihiro Hama, Wataru Suzuki, Kazuyoshi Kawakami, Takahito Sugisaki, Sari Shikibu, Seiichi Matsumoto, Kazuo Sugita, Yu Okawa
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 38:163-169
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da7a34c0eabfbfadff2637a3bb788f82
https://doi.org/10.5649/jjphcs.38.163
https://doi.org/10.5649/jjphcs.38.163
Autor:
Masami Hanade, Takahito Sugisaki, Toshihiro Hama, Hajime Sugiyama, Yasuo Nakamura, Gou Takahashi, Shutaro Higuchi, Maki Nemoto, Kazuyoshi Kawakami, Nao Tunoda, Naoko Kuroda
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 35:129-135
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5ad24630d7f0140491338e4ce7c7560
https://doi.org/10.5649/jjphcs.35.129
https://doi.org/10.5649/jjphcs.35.129
Autor:
Yuma Nonomiya, Takashi Yokokawa, Kazuyoshi Kawakami, Kazuo Kobayashi, Takeshi Aoyama, Tomomi Takiguchi, Takahito Sugisaki, Kenichi Suzuki, Mitsukuni Suenaga, Takeru Wakatsuki, Kensei Yamaguchi, Yoshikazu Sugimoto, Toshihiro Hama
Publikováno v:
Oncology Research; 2019, Vol. 27 Issue 5, p551-556, 6p
Autor:
Kazuyoshi Kawakami, Takashi Yokokawa, Kazuo Kobayashi, Takahito Sugisaki, Kenichi Suzuki, Mitsukuni Suenaga, Kensei Yamaguchi, Ayaka Inoue, Yoshiaki Machida, Toshiharu Yamaguchi, Toshihiro Hama
Publikováno v:
Oncology Research; 2017, Vol. 25 Issue 9, p1625-1631, 7p